ASCO Conference Coverage
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation.
For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports.
Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib.
And even though men...
There are no ASCO Conference Coverage OBR Green articles.